Antimetabolites: Sulfonamides and trimethoprim

Last updated: November 01, 2022

Antimetabolites: Sulfonamides and trimethoprim

A&D

A&D

Haemophilus influenzae
Mycobacterium tuberculosis (Tuberculosis)
Mycoplasma pneumoniae
Chlamydia trachomatis
Chlamydia pneumoniae
Treponema pallidum (Syphilis)
Epstein-Barr virus (Infectious mononucleosis)
Herpes simplex virus
Cytomegalovirus
Parvovirus B19
Human papillomavirus
Influenza virus
HIV (AIDS)
Candida
Cryptococcus neoformans
Pneumocystis jirovecii (Pneumocystis pneumonia)
Aspergillus fumigatus
Plasmodium species (Malaria)
Histoplasmosis
Blastomycosis
Coccidioidomycosis and paracoccidioidomycosis
Cell wall synthesis inhibitors: Penicillins
Cell wall synthesis inhibitors: Cephalosporins
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Miscellaneous protein synthesis inhibitors
Miscellaneous cell wall synthesis inhibitors
DNA synthesis inhibitors: Fluoroquinolones
Antimalarials
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Herpesvirus medications
Integrase and entry inhibitors
Azoles
Echinocandins
Miscellaneous antifungal medications
Vitamin B12 deficiency
Iron deficiency anemia
Aplastic anemia
Anemia of chronic disease
Autoimmune hemolytic anemia
Macrocytic anemia: Pathology review
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Anemia: Clinical
Sickle cell disease (NORD)
Sickle cell disease: Clinical
Alpha-thalassemia
Beta-thalassemia
Hereditary spherocytosis
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Clot retraction and fibrinolysis
Hemolytic-uremic syndrome
Thrombotic thrombocytopenic purpura
Immune thrombocytopenia
Heparin-induced thrombocytopenia
Disseminated intravascular coagulation
Thrombocytopenia: Clinical
Von Willebrand disease
Platelet disorders: Pathology review
Coagulation disorders: Pathology review
Antiplatelet medications
Anticoagulants: Heparin
Anticoagulants: Direct factor inhibitors
Bleeding disorders: Clinical
Wiskott-Aldrich syndrome
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Clinical
Hemophilia
B-cell development
B-cell activation, differentiation, and contraction
T-cell development
T-cell activation
Cell-mediated immunity of CD4 cells
Cell-mediated immunity of natural killer and CD8 cells
Thymic aplasia
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Adenosine deaminase deficiency
DiGeorge syndrome
Vaccinations: Clinical
Complement deficiency
Myasthenia gravis
Antibody classes
X-linked agammaglobulinemia
Type I hypersensitivity
Anaphylaxis
Type II hypersensitivity
Type III hypersensitivity
Type IV hypersensitivity
Graft-versus-host disease
Chronic granulomatous disease
Hyper IgM syndrome
Glucocorticoids
Non-corticosteroid immunosuppressants and immunotherapies
Introduction to the immune system
Innate immune system
Cytokines
Somatic hypermutation and affinity maturation
VDJ rearrangement
MHC class I and MHC class II molecules
Lymphomas: Pathology review
Non-Hodgkin lymphoma
Hodgkin lymphoma
Leukemias: Pathology review
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Plasma cell disorders: Pathology review
Complement system

Transcript

Watch video only

Antimetabolites are medications that interfere with the synthesis of DNA.

Some antimetabolites are used in chemotherapy to kill cancer cells, while others are used as antibiotics since they inhibit bacterial folate synthesis.

Folate, or folic acid, also known as vitamin B9, is necessary for the synthesis of nucleic acids, which are the building blocks of DNA and RNA.

Simply put, a lack of folate results in a lack of nucleic acids, which then results in decreased DNA and RNA synthesis, leading to hindered cell division and function.

Now, a key difference between our cells and bacterial cells is that we get all of our folate through our diet, while bacteria can make their own folate from scratch.

Because of this, we can target the bacterial folate synthesis pathway to minimize the damage done to our cells.

So in order to synthesize folate, the bacteria will first use the host’s para-aminobenzoic acid, or pABA, and convert it to dihydropteroic acid via the enzyme dihydropteroate synthetase, or DHPS.

In the second step, dihydropteroic acid is converted into dihydrofolic acid by dihydrofolate synthetase.

The third step is the conversion of dihydrofolic acid into tetrahydrofolic acid via dihydrofolate reductase.

Tetrahydrofolic acid is a folic acid derivative and can be used to synthesize purines like adenine and guanine, which are used to build DNA and RNA, as well as thymidine, which is only used in DNA.

Now, the first group of antimetabolite antibiotics are the sulfonamides, which include sulfamethoxazole, or SMX, sulfisoxazole, and sulfadiazine.

These medications bind to dihydropteroate synthetase, or DHPS, in the first step of folate synthesis and prevents the bacteria from making dihydropteroic acid.

These medications can be given peroral or injected into a vein, but they need to be metabolized by the liver in order to work.

Now, they are broad spectrum and can treat a variety of gram positive and gram negative bacteria, as well as chlamydia and nocardia species.

Next we have trimethoprim, which inhibits the 3rd step of folate synthesis by inhibiting dihydrofolate reductase, or DHFR, preventing the formation of tetrahydrofolic acid.

Now humans also have dihydrofolate reductase, but the bacterial version of this enzyme is 4-5 times more sensitive to this medication.

Trimethoprim is also broad spectrum and is effective against both gram positive and gram negative bacteria.

Now, it’s mainly used in combination with sulfamethoxazole. The combination of these medications is called TMP/SMX.

These medications are used together because they are synergistic and can block folate synthesis at two key steps.

When used alone, both medications are bacteriostatic, meaning they can stop the bacteria from reproducing.

But when combined, they are bactericidal, meaning they will kill off the bacteria.

TMP/SMX is most commonly used to treat traveler's diarrhea and simple urinary tract infections, but it’s also effective in treating pneumonia and sinus infections caused by haemophilus influenzae and moraxella catarrhalis.

It’s the first line therapy for the treatment and prevention of pneumocystis jirovecii infections, which are caused by a yeast-like fungus that can affect immunocompromised people.

Finally, it’s effective against Methicillin Resistant Staph. Aureus, or MRSA.

A few bacteria exist that are notably not susceptible to antimetabolites, and those are Pseudomonas aeruginosa and bacteria from the Mycoplasma family.

Okay for side effects, some people are allergic to sulfonamide and can develop a hypersensitivity reaction to these antibiotics.

They can also develop a cross reaction with other drugs that contain the sulfonamide functional group such as glyburide, a diabetic medication, and thiazide diuretics.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Methotrexate, and trimethoprim-sulfamethoxazole: toxicity from this combination continues to occur" Can Fam Physician (2014)
  5. "Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate" Journal of Pediatric Hematology/Oncology (2016)
  6. "Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis" New England Journal of Medicine (1995)